Adam Feuerstein articles over last 30 days

- articles last 30 days - articles per day
Mentioned in this news Places Companies People
2014/09/30 11:22
2014/09/30 11:22
4h
Catalyst reported positive results from a phase III study of Firdapse as a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS), a progressive, muscle-weakening disease. Treatment with Firdapse...
2014/09/30 11:22
2014/09/30 11:22
Latest videos
2014/09/29 14:22
2014/09/29 14:22
1d
In the study (known as AETHERA), treatment with Adcetris in "high risk" Hodgkin lymphoma patients immediately after a stem-cell transplant led to a 43% reduction in the risk of disease progression...
2014/09/27 22:19
2014/09/27 22:19
2d
The past couple of weeks should have been heady ones for Bethesda-based Northwest Biotherapeutics. The small biotech firm, with an innovative new vaccine treatment for brain, prostate and other...
2014/09/26 11:22
2014/09/26 11:22
4d
The next big pipeline event from Vertex is the phase II study of VX-661 in homozygous F508del cystic fibrosis patients. Data expected early next year. Again, I'm hearing Vertex management sounds...
2014/09/24 13:22
2014/09/24 13:22
6d
BOSTON ( TheStreet) -- Adam, since you like talking to yourself about biotech stocks, I was hoping you could help me figure out Alcobra(ADHD) . The announcement of results from the phase III study of...
2014/09/22 17:22
2014/09/22 17:22
7d
FOSTER CITY, Calif. ( TheStreet) -- Gilead Sciences(GILD) has been on an incredible stock-flying run because of its hepatitis C drugs, but now you're telling me investors are swinging their attention...
2014/09/21 04:22
2014/09/21 04:22
9d
BOSTON ( TheStreet) -- The Areniacs -- my term of endearment for the retail-investor supporters of Arena Pharmaceuticals (ARNA) -- have been burning up the Internet message boards for the past few...
2014/09/16 14:22
2014/09/16 14:22
14d
BOSTON ( TheStreet) -- The Areniacs -- my term of endearment for the retail-investor supporters of Arena Pharmaceuticals (ARNA) -- have been burning up the Internet message boards for the past few...
2014/09/15 14:22
2014/09/15 14:22
15d
BEDMINSTER, NJ ( TheStreet) -- NPS Pharmaceuticals(NPSP) shares are down 11% in early Monday trading following a rough outing for its hormone replacement therapy Natpara at an FDA advisory panel on...
2014/09/13 08:31
2014/09/13 08:31
17d
Amarin Corp. plc revealed more bad news Friday from the U.S. Food and Drug Administration, which denied the company's appeal of a decision that effectively quashed hopes that the biotech would be...
2014/09/11 14:22
2014/09/11 14:22
19d
The condition of Dr. Rick Sacra, the doctor who contracted Ebola while treating patients in West Africa, continues to improve following treatment at Nebraska Medical Center. Officials at the hospital...
2014/09/08 11:22
2014/09/08 11:22
22d
Keryx Biopharmaceuticals(KERX) secured FDA approval for "Zerenex" on Friday, but the drug's label is weak, which is going to make it difficult for the company to market the new phosphate binder...
2014/09/05 13:22
2014/09/05 13:22
25d
Roman asks, "Adam, in your latest articles discussing the important biotech events for the rest of the year, I noticed you made no mention of Achillion Pharmaceuticals. Is this because you don't see...
2014/09/03 16:22
2014/09/03 16:22
26d
Ampio insists the "temperature excursion" problem with the Ampion drug supply discovered in the "STEPS" study is only a temporary setback which will be rectified with results from another, ongoing...
2014/09/03 11:22
2014/09/03 11:22
27d
Under terms of the partnership, Abbvie is paying Infinity $275 million in upfront cash to license worldwide rights to IPI-145, an oral drug designed to block a protein known as PI3K critical for tumor...
2014/09/02 14:22
2014/09/02 14:22
28d
SOUTH SAN FRANCISCO (TheStreet) -- The Exelixis(EXEL) cancer drug cabozantinib failed to prolong survival in men with advanced prostate cancer, according to results from a phase III study announced...
2014/09/30 11:22
2014/09/30 11:22
Latest from Twitter